CLN Celon Pharma S.A.
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Celon Pharma (WSE: CLN)
›
Celon Pharma (WSE: CLN) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 560 employees.
The shares were at 15.64 PLN on 19 November 2026, down 27.9% over 52 weeks. Its 52-week range is 15.20 PLN to 23.50 PLN: the price is 33.4% below the high and 2.9% above the low.
At a market capitalisation of 843.18M PLN, it trades at 7.7 times trailing earnings and 9.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 69% for CLN.
Celon Pharma reports return on equity of -21.8%, an operating margin of -1.9% and flat revenue year over year.
Its debt exceeds its cash by 93.91M PLN. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock; their mean price target of 20.38 PLN is 30.3% above the current price.